Compare AZI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZI | ASRT |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 75.1M |
| IPO Year | 2024 | 1997 |
| Metric | AZI | ASRT |
|---|---|---|
| Price | $2.72 | $9.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 9.4M | 52.4K |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,466,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.90 | 9.22 |
| 52 Week Low | $1.33 | $7.71 |
| 52 Week High | $69.00 | $15.15 |
| Indicator | AZI | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 62.11 | 89.36 |
| Support Level | $3.12 | $8.61 |
| Resistance Level | $4.22 | $10.42 |
| Average True Range (ATR) | 0.71 | 0.27 |
| MACD | 0.07 | 0.99 |
| Stochastic Oscillator | 44.81 | 89.19 |
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.